Literature DB >> 27475806

Evolving Immunotherapy Approaches for Renal Cell Carcinoma.

Susanna A Curtis1, Justine V Cohen1, Harriet M Kluger2.   

Abstract

Metastatic renal cell carcinoma (mRCC) continues to be associated with high rates of morbidity and mortality. Renal cell carcinoma (RCC) is typically resistant to cytotoxic chemotherapy, and while targeted therapies have activity and prolong progression-free and overall survival, responses are usually not durable. Modulating the immune system with cytokine therapy, vaccine therapy, cell therapy, and checkpoint inhibitors offers hope of prolonged survival. Standard and emerging immune therapy approaches and combinations of immune therapies and other modalities are reviewed.

Entities:  

Keywords:  Adoptive cell therapy; Cytokines; Immune checkpoint inhibitors; Immunotherapy; Renal cell carcinoma; Vaccine therapy

Mesh：

Substances：

Year:  2016        PMID： 27475806     DOI： 10.1007/s11912-016-0542-9

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.945


  70 in total

1.  An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial.

Authors:  Christopher Wood; Pramod Srivastava; Ronald Bukowski; Louis Lacombe; Andrei I Gorelov; Sergei Gorelov; Peter Mulders; Henryk Zielinski; Axel Hoos; Florentina Teofilovici; Leah Isakov; Robert Flanigan; Robert Figlin; Renu Gupta; Bernard Escudier
Journal:  Lancet       Date:  2008-07-03       Impact factor: 79.321

Review 2.  Emerging role for novel immunotherapy agents in metastatic renal cell carcinoma: from bench to bedside.

Authors:  Matthew Weinstock; David F McDermott
Journal:  Am Soc Clin Oncol Educ Book       Date:  2015

3.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

4.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Authors:  Julie R Brahmer; Charles G Drake; Ira Wollner; John D Powderly; Joel Picus; William H Sharfman; Elizabeth Stankevich; Alice Pons; Theresa M Salay; Tracee L McMiller; Marta M Gilson; Changyu Wang; Mark Selby; Janis M Taube; Robert Anders; Lieping Chen; Alan J Korman; Drew M Pardoll; Israel Lowy; Suzanne L Topalian
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

5.  Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.

Authors:  David F McDermott; Meredith M Regan; Joseph I Clark; Lawrence E Flaherty; Geoffery R Weiss; Theodore F Logan; John M Kirkwood; Michael S Gordon; Jeffrey A Sosman; Marc S Ernstoff; Christopher P G Tretter; Walter J Urba; John W Smith; Kim A Margolin; James W Mier; Jared A Gollob; Janice P Dutcher; Michael B Atkins
Journal:  J Clin Oncol       Date:  2005-01-01       Impact factor: 44.544

6.  Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma.

Authors:  Robert J Motzer; Gary Hudes; George Wilding; Lawrence H Schwartz; Subramanian Hariharan; Susan Kempin; Rana Fayyad; Robert A Figlin
Journal:  Clin Genitourin Cancer       Date:  2009-01       Impact factor: 2.872

7.  Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.

Authors:  S A Rosenberg; J C Yang; S L Topalian; D J Schwartzentruber; J S Weber; D R Parkinson; C A Seipp; J H Einhorn; D E White
Journal:  JAMA       Date:  1994 Mar 23-30       Impact factor: 56.272

8.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

9.  A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study.

Authors:  Uday B Dandamudi; Musie Ghebremichael; Jeffrey A Sosman; Joseph I Clark; David F McDermott; Michael B Atkins; Janice P Dutcher; Walter J Urba; Meredith M Regan; Igor Puzanov; Todd S Crocenzi; Brendan D Curti; Ulka N Vaishampayan; Nancy A Crosby; Kim A Margolin; Marc S Ernstoff
Journal:  J Immunother       Date:  2013 Nov-Dec       Impact factor: 4.456

10.  Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results.

Authors:  Asim Amin; Arkadiusz Z Dudek; Theodore F Logan; Raymond S Lance; Jeffrey M Holzbeierlein; Jennifer J Knox; Viraj A Master; Sumanta K Pal; Wilson H Miller; Lawrence I Karsh; Irina Y Tcherepanova; Mark A DeBenedette; W Lee Williams; Douglas C Plessinger; Charles A Nicolette; Robert A Figlin
Journal:  J Immunother Cancer       Date:  2015-04-21       Impact factor: 13.751
View more
  7 in total

Review 1.  Immunotherapy for Brain Tumors.

Authors:  Lan B Hoang-Minh; Duane A Mitchell
Journal:  Curr Treat Options Oncol       Date:  2018-10-11

Review 2.  Intraperitoneal immunotherapy: historical perspectives and modern therapy.

Authors:  W F Morano; A Aggarwal; P Love; S D Richard; J Esquivel; W B Bowne
Journal:  Cancer Gene Ther       Date:  2016-11-11       Impact factor: 5.987

3.  Reduced E-cadherin facilitates renal cell carcinoma progression by WNT/β-catenin signaling activation.

Authors:  Xinqi Zhang; Mingxi Yang; Hua Shi; Jianxin Hu; Yuanlin Wang; Zhaolin Sun; Shuxiong Xu
Journal:  Oncotarget       Date:  2017-03-21

4.  Molecular Characterization and Putative Pathogenic Pathways of Tuberous Sclerosis Complex-Associated Renal Cell Carcinoma.

Authors:  Jeong Hwan Park; Cheol Lee; Mee Soo Chang; Kwangsoo Kim; Seongmin Choi; Hyunjung Lee; Hyun-Seob Lee; Kyung Chul Moon
Journal:  Transl Oncol       Date:  2018-06-18       Impact factor: 4.243

5.  Memory stem T cells generated by Wnt signaling from blood of human renal clear cell carcinoma patients.

Authors:  Cihui Yan; Jingjing Chang; Xinmiao Song; Fan Yan; Wenwen Yu; Yang An; Feng Wei; Lili Yang; Xiubao Ren
Journal:  Cancer Biol Med       Date:  2019-02       Impact factor: 4.248

6.  Identification of pyrrolopyrimidine derivative PP-13 as a novel microtubule-destabilizing agent with promising anticancer properties.

Authors:  Pauline Gilson; Fernando Josa-Prado; Claire Beauvineau; Delphine Naud-Martin; Laetitia Vanwonterghem; Florence Mahuteau-Betzer; Alexis Moreno; Pierre Falson; Laurence Lafanechère; Véronique Frachet; Jean-Luc Coll; Jose Fernando Díaz; Amandine Hurbin; Benoit Busser
Journal:  Sci Rep       Date:  2017-08-31       Impact factor: 4.379

Review 7.  Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis.

Authors:  Anusha Thadi; Marian Khalili; William F Morano; Scott D Richard; Steven C Katz; Wilbur B Bowne
Journal:  Vaccines (Basel)       Date:  2018-08-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.